The FDA’s Antimicrobial Drugs Advisory Committee is slated to meet on January 11, 2018 to recommend approval or disapproval of Aradigm Corp.’s (ARDM) New Drug Application for Linhaliq.The Company is seeking approval of Linhaliq for the treatment of non-cystic fibrosis bronchiectasis (NCFBE) patients with chronic infections with Pseudomonas aeruginosa (P. aeruginosa).Linhaliq is composed of a mixture of liposome encapsulated and unencapsulated Ciprofloxacin, a widely prescribed antibiotic that is available in oral and intravenous formulations.Cipro DPI, or Ciprofloxacin dry powder for inhalation, a therapy to treat non-cystic fibrosis bronchiectasis, developed by Bayer, failed to win FDA panel backing last month due to inconsistent data, concern over drug-resistance and failure to meet all but only one of the primary endpoints in two trials.It remains to be seen which way the panel is going to vote for Linhaliq. The FDA’s final decision is slated for January 26, 2018.ARDM closed Tuesday’s (Dec.26) trading at $5.59, up 4.88%.